Edition:
United States

STADA Arzneimittel AG (STAGn.DE)

STAGn.DE on Xetra

81.14EUR
11:35am EDT
Change (% chg)

€-0.34 (-0.42%)
Prev Close
€81.48
Open
€81.42
Day's High
€81.98
Day's Low
€81.00
Volume
18,629
Avg. Vol
49,555
52-wk High
€90.24
52-wk Low
€56.51

Select another date:

Thu, May 3 2018

BRIEF-STADA Says On Track To Meet Targets After Q1 Results

* DGAP-NEWS: STADA ARZNEIMITTEL AG: STADA WITH SOLID BUSINESS DEVELOPMENT IN THE FIRST QUARTER OF 2018

BRIEF-STADA Says Miguel Pagan To Become Head of Production

* SAYS MIGUEL PAGAN TO BECOME EXECUTIVE BOARD MEMBER FOR PRODUCTION AND DEVELOPMENT

BRIEF-Board Of STADA To File Application Related To Change Of Sub-Segment Of Stock Exchange

* DGAP-ADHOC: STADA ARZNEIMITTEL AG: EXECUTIVE BOARD OF STADA ARZNEIMITTEL AG DECIDES TO FILE APPLICATION RELATED TO CHANGE OF SUB-SEGMENT OF THE STOCK EXCHANGE

BRIEF-STADA Arzneimittel: Domination And Profit And Loss Transfer Agreement Takes Effect

* DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT BETWEEN STADA ARZNEIMITTEL AG AND NIDDA HEALTHCARE GMBH TAKES EFFECT / BEGINNING OF ACCEPTANCE PERIOD FOR SEVERANCE OFFER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-STADA Says Domination And Profit And Loss Transfer Agreement With Nidda Healthcare GmbH Takes Effect

* STADA SAYS DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT BETWEEN STADA ARZNEIMITTEL AG AND NIDDA HEALTHCARE GMBH TAKES EFFECT

Stada cuts dividend to focus on investments

BERLIN, March 8 German pharamceuticals company Stada is cutting its dividend to instead use the money for investments to grow its business and improve its position in the market.

BRIEF-Stada FY Net Income Down By 1 Pct At EUR 85.3 Mln

* GROUP SALES INCREASED IN 2017 FINANCIAL YEAR BY 8% TO EUR2,313.9M

BRIEF-STADA to propose a dividend of 0.11 euros per share

* DGAP-ADHOC: STADA: EXECUTIVE BOARD AND SUPERVISORY BOARD OF STADA ARZNEIMITTEL AG RESOLVE ON A PROPOSAL FOR THE APPROPRIATION OF PROFITS AND PROPOSE A DIVIDEND IN THE AMOUNT OF EUR0.11 PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Stada Says EMA Starts Evaluation Of Resubmitted Pegfilgrastim Application

* DGAP-NEWS: STADA ARZNEIMITTEL AG: EMA STARTED THE EVALUATION OF RESUBMITTED MARKETING AUTHORISATION APPLICATION FOR BIOSIMILAR PEGFILGRASTIM

Stada names new CEO to replace Albrecht

FRANKFURT Stada on Thursday named Peter Goldschmidt to take over as chief executive from Sept. 1, replacing Claudio Albrecht after less than a year in office.

Select another date: